Prehypertension is real and can be associated with target organ damage

Journal of the American Society of Hypertension

Volumn 11, Issue 11, 2017, Pages 704-708

  Materson, Barry J ^a   Garcia Estrada, Manuel ^a   Degraff, Stephane B ^a   Preston, Richard A ^a,b,c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b JACKSON MEMORIAL HOSPITAL   (United States)

^c FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

Cognitive function; drug treatment; end stage renal disease; left ventricular hypertrophy

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; ARTERIOSCLEROSIS; CARDIOVASCULAR RISK; COGNITIVE DEFECT; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE COURSE; END STAGE RENAL DISEASE; EPIDEMIOLOGICAL DATA; FRAMINGHAM RISK SCORE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HEREDITY; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; PREHYPERTENSION; PRIORITY JOURNAL; REVIEW; SYSTOLIC BLOOD PRESSURE; TARGET ORGAN; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; DISEASE EXACERBATION; DRUG EFFECT; GENETICS; HEART LEFT VENTRICLE HYPERTROPHY; INCIDENCE; LIFESTYLE; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR;

ANTIHYPERTENSIVE AGENTS; ARTERIOSCLEROSIS; BLOOD PRESSURE; COGNITIVE DYSFUNCTION; DISEASE PROGRESSION; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INCIDENCE; KIDNEY FAILURE, CHRONIC; LIFE STYLE; PREHYPERTENSION; RISK FACTORS;

EID: 85030773478     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2017.09.005     Document Type: Review

References (28)

1. Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo, J.L. Jr., et al., National High Blood Pressure Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 289 (2003), 2560–2572.
2. Vasan, R.S., Larson, M.G., Leip, E.P., Evans, J.C., O'Donnell, C.J., Kannel, W.B., et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 345 (2001), 1291–1297.
3. Chobanian, A.V., Prehypertension revisited. Hypertension 48 (2006), 812–814.
4. Russell, L.B., Valiyeva, E., Carson, J.L., Effects of prehypertension on admissions and deaths. A simulation. Arch Intern Med 164 (2004), 2119–2124.
5. Julius, S., Nesbitt, S.D., Egan, B.M., Weber, M.A., Michelson, E.L., Kaciroti, N., et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354 (2006), 1685–1697.
6. He, D.H., Lin, J.X., Zhang, L.M., Xu, C.S., Xie, Q., Early treatment with losartan effectively ameliorates hypertension and improves vascular remodeling in a prehypertensive rat model. Life Sci 173 (2017), 20–27.
7. Materson, B.J., Reda, D.J., Cushman, W.C., Massie, B.M., Freis, E.D., Kochar, M.S., et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 328 (1993), 914–921.
8. Jennings, J.R., Muldoon, M.F., Ryan, C., Gach, H.M., Heim, A., Sheu, L.K., et al. Prehypertensive blood pressures and regional cerebral blood flow independently relate to cognitive performance in midlife. J Am Heart Assoc, 6, 2017, e004856.
9. Jung, J.Y., Park, S.K., Oh, C.M., Kang, J.G., Choi, J.M., Ryoo, J.H., et al. The influence of prehypertension, controlled and uncontrolled hypertension on left ventricular diastolic function and structure in the general Korean population. Hypertens Res 40 (2017), 606–612.
10. Oyama, J.I., Node, K., Prevalence of prehypertension and left ventricular hypertrophy. Hypertens Res 40 (2017), 544–545.
11. Yaşar, E., Taşolar, H., Açikgöz, N., Left ventricular myocardial performance index in prehypertensive patients with normal coronary arteries. Blood Press Monit 22 (2017), 149–153.
12. Leiba, A., Twig, G., Vivante, A., Skorecki, K., Golan, E., Derazne, E., et al. Prehypertension among 2.19 million adolescents and future risk for end-stage renal disease. J Hypertens 35 (2017), 1290–1296.
13. Alpaydin, S., Turan, Y., Caliskan, M., Caliskan, Z., Aksu, F., Ozyildirim, S., et al. Morning blood pressure surge is associated with carotid intima-media thickness in prehypertensives patients. Blood Press Monit 22 (2017), 131–136.
14. Ishikawa, Y., Ishikawa, J., Ishikawa, S., Kario, K., Kajii, E., Jichi Medical School Cohort Investigators Group. Progression from prehypertension to hypertension and risk of cardiovascular disease. J Epidemiol 27 (2017), 8–13.
15. Jung, M.H., Ihm, S.H., Lee, D.H., Chung, W.B., Jung, H.O., Youn, H.J., Prehypertension is associated with early complications of atherosclerosis but not with exercise capacity. Int J Cardiol 227 (2017), 387–392.
16. Lehmann, N., Erbel, R., Mahabadi, A.A., Kälsch, H., Möhlenkamp, S., Moebus, S., et al. Accelerated progression of coronary artery calcification in hypertension but also prehypertension. J Hypertens 34 (2016), 2233–2242.
17. Vasan, R.S., Larson, M.G., Leip, E.P., Kannel, W.B., Levy, D., Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 358 (2001), 1682–1686.
18. Vasan, R.S., Beiser, A., Seshadri, S., Larson, M.G., Kannel, W.B., D'Agostino, R.B., et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 287 (2002), 1003–1010.
19. Franklin, S.S., Pio, J.R., Wong, N.D., Larson, M.G., Leip, E.P., Vasan, R.S., et al. Predictors of new-onset diastolic and systolic hypertension: the Framingham Heart Study. Circulation 111 (2005), 1121–1127.
20. Greenlund, K.J., Croft, J.B., Mensah, G.A., Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1999-2000. Arch Intern Med 164 (2004), 2113–2118.
21. Qureshi, A.I., Suri, M.F., Kirmani, J.F., Divani, A.A., Mohammad, Y., Is prehypertension a risk factor for cardiovascular diseases?. Stroke 36 (2005), 1859–1863.
22. Zhang, Y., Lee, E.T., Devereux, R.B., Yeh, J., Best, L.G., Fabsitz, R.R., et al. Prehypertension, diabetes, and cardiovascular disease risk in a population-based sample: the Strong Heart Study. Hypertension 47 (2006), 410–414.
23. Hsia, J., Margolis, K.L., Eaton, C.B., Wenger, N.K., Allison, M., Wu, L.L., et al. Prehypertension and cardiovascular disease risk in the Women's Health Initiative. Circulation 115 (2007), 855–860.
24. Toprak, A., Wang, H., Chen, W., Paul, T., Ruan, L., Srinivasan, S., et al. Prehypertension and black-white contrasts in cardiovascular risk in young adults: Bogalusa Heart Study. J Hypertens 27 (2009), 243–250.
25. Shen, L., Ma, H., Xiang, M.X., Wang, J.A., Meta-analysis of cohort studies of baseline prehypertension and risk of coronary heart disease. Am J Cardiol 112 (2013), 266–271.
26. Pal, G.K., Adithan, C., Umamaheswaran, G., Pal, P., Nanda, N., Indumathy, J., et al. Endothelial nitric oxide synthase gene polymorphisms are associated with cardiovascular risks in prehypertensives. J Am Soc Hypertens 10 (2016), 865–872.
27. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362 (2010), 1575–1585.
28. The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373 (2015), 2103–2116.